Table 2 Patient characteristics for de novo DLBCL and transformed lymphomas.

From: A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study

 

de novo DLBCL

Transformed

p value

 

N = 51,215

N = 871

 

Age at diagnosis, median (IQR)

66 (55–75)

64 (57–71)

0.001

Age category

  

<0.001

 18–44

6271 (12%)

26 (3%)

 

 45–54

6516 (13%)

142 (16%)

 

 55–64

11,206 (22%)

270 (31%)

 

 65–74

13,168 (26%)

322 (37%)

 

 75–89

14,054 (27%)

111 (13%)

 

Sex

  

0.27

 Female

22,552 (44%)

400 (46%)

 

 Male

28,663 (56%)

471 (54%)

 

Race

  

<0.001

 White

41,415 (81%)

762 (87%)

 

 Black

3919 (8%)

39 (4%)

 

 Other

5375 (10%)

66 (8%)

 

 Missing

506 (1%)

4 (<1%)

 

Ann Arbor stage

  

<0.001

 Stage I-II

20,714 (40%)

274 (31%)

 

 Stage III_IV

27,594 (54%)

508 (58%)

 

 Missing

2907 (6%)

89 (10%)

 

B symptoms

  

<0.001

 No B symptoms

28,015 (55%)

488 (56%)

 

 B symptoms

14,618 (29%)

161 (18%)

 

 Missing

8582 (17%)

222 (25%)

 
  1. DLBCL diffuse large B-cell lymphoma.
Back to article page